

INFORMAȚII PERSONALE

DAN GHEORGHE-ANDREI



📍 Sos. Kiseleff, nr.22, Bucuresti, Romania

☎️ +40 744151725

✉️ andrei.dan@gadan.ro

Sexul Masculin | Data nașterii 04/05/1952 | Naționalitatea română

EXPERIENȚA PROFESIONALĂ

2006 - prezent

Profesor universitar; Cercetator St. Gr. 1 (hon)
Universitatea de Medicină și Farmacie „Carol Davila”
Dionisie Lupu, nr.37, sector 1, București, 020022, Romania

- Invatamant universitar, anii : 4, 5, 6 (cardiovascular, optional, urgente medicale) (cursuri + lucrari practice/seminarii)
- Invatamant postuniversitar
- Cercetare
- Invățământ pentru medicii rezidenți

2004- prezent

Tipul sau sectorul de activitate : Invățământ medical
Expert evaluator

- Expert evaluator pentru granturi CNCSIS, CNMP și pentru granturi de excelență CEEEX

2000-2006

Conferențiar universitar

- Invățământ superior și cercetare științifică

2002-prezent

Medic primar cardiolog

2001

Cercetător științific gr.I

- Cercetare științifică

2000 - prezent

Cardiolog european (ISCED 6)
European Board for the Specialty of Cardiology

1996 - 2000

Sef de lucrări

1990 - 1996

Asistent universitar

1998

Doctor în medicină (ISCED 6)

1991

Medic primar medicină internă (ISCED 6)

1977

Doctor – medic (ISCED 5)

EDUCAȚIE ȘI FORMARE

[Adăugați câmpuri separate pentru fiecare etapă de formare. Începeți cu cea mai recent.]

DATA		Nivel EQF
2003	Curs intensiv postuniversitar: "Cardiology Summit Training, Harvard Medical School" -	8
2000	Training in Studii Clinice (Hong-Kong)	
1998	Doctor in medicina cu teza "Locul electrofiziologiei interventionale in tratamentul tahicardiilor simptomatice"	
1996	Pregatire post-universitara "Good Clinical Practice" (Praga)	
1995	Supraspecializare in ritmologie interventionala - Université Catholique de Louvain-Cliniques Universitaires de Mont-Godinne, Belgia	
1993-1995	Specializare postuniversitara in Ritmologie Interventionala – Université Catholique de Louvain - Cliniques Universitaires de Mont-Godinne, Belgia	
1993-1996	Pregatire postuniversitara cardiologie	
1989-1990	Curs postuniversitar cardiologie	

1988	Curs postuniversitar de Pedagogie medicala
1980-1984	Asistent universitar – secundariat de medicina interna
1976-1980	Intern de medicina interna
1971-1977	Facultatea de Medicina Generala, Institutul de Medicina si Farmacia « Carol Davila » Bucuresti

COMPETENTE PERSONALE

Limba(i) maternă(e) Română

Alte limbi străine cunoscute

	INTELEGERE		VORBIRE		SCRIERE
	Ascultare	Citire	Participare la conversație	Discurs oral	
Limba engleză	C2 Utilizator experimentat	C2 Utilizator experimentat	C2 Utilizator experimentat	C2 Utilizator experimentat	C2 Utilizator experimentat
Limba franceză	C2 Utilizator experimentat	C2 Utilizator experimentat	C2 Utilizator experimentat	C2 Utilizator experimentat	C2 Utilizator experimentat

Niveluri: A1/2: Utilizator elementar - B1/2: Utilizator independent - C1/2: Utilizator experimentat
Cadru european comun de referință pentru limbi străine

Competențe de comunicare

- Bune competențe de comunicare dobândite prin experiența proprie în învățământ, conferințe

Alte specializări și calificări

- Investigator principal in 30 studii multicentrice internationale si 4 studii multicentrice nationale
- Monitor clinic pentru 2 studii clinice internationale
- Coordonator National: 3 studii multicentrice
- Organizator a 4 conferinte internationale si a 2 simpozioane internationale (1996-1999, 2007,2009)
- Organizator al unui numar de 7 cursuri internationale – 1997 -1999, Bucuresti
- Cofondator al parteneriatului medical “Université Catholique de Louvain – Cliniques Universitaires de Mont-Godinne – Spitalul Clinic “N.Gh.Lupu”
- Coordonator al Programului pedagogic medical (inclus in programul COPBIL)

Competențe organizaționale/manageriale

- Organizarea Simpozionului cu participare internationala “Heart Rhythm Update” – trei editii (2007, 2009, 2011)
- Organizarea Congresului international ISCP (chairman): 2012, 2013
- Organizarea programului de registru si constientizare in fibrilatia atriala FACTS
- Director de proiect - nr. Contract 41-061 Parteneriate PN II (2008-2010)
- - Manager proiect POSTDRU « Excellin »

Competențe dobândite la locul de muncă

- Foarte buna capacitate de comunicare (rezultatul a 34 de ani de activitate didactica universitara si al activitatii de 18 ani de sustinere de seminarii si conferinte nationale si internationale. Participant ca student si ca profesor la sesiuni de invatamant de aptitudini de comunicare)
- Spirit de echipa (membru in echipe de cercetare, echipe redactionale, societati profesionale si culturale)
- Capacitate de adaptare la medii multiculturale (experienta de munca in echipe de cardiologie in Belgia, Israel. Membru in comitetul de directori si guvernator pentru Romania al International Society of Cardiovascular Pharmacotherapy)
- Leadership (in prezent conducatorul Sectiei de Cardiologie a Spitalului Clinic Colentina – echipa formata din 30 persoane; seful de Catedra/Disciplina Medicina Interna – Sp. Clinic Colentina – echipa formata din 22 persoane; secretarul stiintific al Facultatii de Medicina – UMF „Carol Davila” Bucuresti; investigator principal si coordonator al echipei de cercetare clinica de cardiologie din Spitalul Clinic Colentina)
- Spirit organizatoric (organizator al cursurilor medicale romano-belgiene in sesiunile 1996-1999.
- Organizator a 2 Conferinte de cardiologie romano-belgiene – 1996 si 2000.
- Organizator al Simpozionului international Heart Rhythm Update 2007 si 2009)

Competențe informatice

- O bună cunoaștere a instrumentelor Microsoft Office™, statistică, căutarea informației medicale

Alte competențe

- Echiparea Laboratorului de explorari cardiovasculare si ritmologie din Spitalul Clinic Colentina
- Echiparea Laboratorului explorari CV si de electrofiziologie interventionala din Spitalul Clinic Colentina

Apartenențe la organizații profesionale

- International Fellow al *American Heart Association*
- Membru in comitetul de directori si guvernator pentru Romania al *International Society of Cardiovascular Pharmacotherapy*
- Fellow al *European Society of Cardiology*, 2003
- Cardiolog European ales de către European Board for the Speciality of Cardiology (EBSC), martie 2000 (inaugural)
- Membru al Societății Europene de Cardiologie (ESC)
- Membru constitutiv *European Heart Rhythm Association*
- Membru in board EHRA (Scientific Documents Committee si Nationalities)
- Cofondator al « Initiativei Est-Centru Europene pentru electrofiziologie interventionala », parte componenta a EHRA
- Premium Professional - Silver Member of *American Heart Association* (curricular - 2003)
- Membru în Consiliul Științific (Clinical Cardiology) al *American Heart Association* (1999)
- Membru al Council on Arteriosclerosis, Thrombosis & Vascular Biology, Council on Clinical Cardiology, Working Group on Atherosclerotic Peripheral Vascular Disease of *American Heart Association / American Stroke Association*
- Membru al Grupului de Lucru pentru Valvulopatii al Societății Europene de Cardiologie (din 1996)
- Membru al Grupului de Lucru pentru Aritmii al Societății Europene de Cardiologie (din 1997)
- Membru Constitutiv al *European Heart Rythm Association (EHRA)* - 2004
- Membru Constitutiv al *Heart Failure Association (HFA)* - 2004
- Membru al RETAC (Reseau Europeen pour le Traitement des Arythmies Cardiaques) - reprezentantul României
- Membru fondator și responsabil de partea română al parteneriatului “*Université Catholique de Louvain – Cliniques Universitaires Saint Luc și Mont-Godinne și Spitalul Clinic Universitar Colentina, Fundația “N.Gh.Lupu”*”
- Membru in Faculty pentru rețelele « CREATE » si « SPAF »
- Redactor Sef – *Romanian Journal of Internal Medicine*
- Associate Editor – *Journal of the Toyal Society of Medicine – Cardiovascular*
- Editorial Board: *Cardiovascular Drugs and Therapy*, Springer

Permis de conducere

- B

INFORMATII SUPLIMENTARE

 Distincții
Premii

- Bursa republicana si Nationala pentru merit – 1975 – 1977
- 7 premii de cercetare in perioada Facultatii
- Distinguished Faculty Award of the University of Medicine and Pharmacy Carol Davila
- Special grant “Dr. Constantinescu”, 1978
- Diploma for Outstanding professional merit, 1977
- Best Clinical Study, 2000 (Palma de Mallorca)
- International Cardiovascular Summit, Harvard Medical School, 2002
- Diploma for participation in EuroHeart Survey, 2003, 2004
- Diploma as “Expert in Evaluation of Scientific Grants” (Education and Research Ministry) - 2004

 Experiența acumulată
(în special managerială) în alte
programe/proiecte
naționale/internaționale

- Studierea sistemului biologic integrativ reprezentat de efectul cardiovascular al obezității, prin utilizarea unor tehnici ecografice, scintigrafice și de modelare matematică, în vederea definirii cardiomiopatiei specifice obezității și a predicției insuficienței cardiace. (nr. Contract 41-061 Parteneriate PN II) – *Director de proiect*
- “Cariera de excelență în cercetare și societatea cunoașterii prin finanțarea studiilor universitare de doctorat (EXCEL-FIN)”. Nr. de identificare a proiectului POSDRU/107/1.5/S/82839 – *Manager de proiect*
- „Sprijinirea cercetării prin formarea de specialiști în cadrul programului de studii postdoctorale”. Numărul de identificare a contractului: POSDRU/89/1.5/S/64109 - *expert*
- Moxonidine in combination treatment of essential hypertension in postmenopausal women - Protocol B3N-VI-S001
- A 3 and a half months open label study to evaluate the efficacy, tolerability and safety of Plendil administration in patients with hypertension - Protocol 02/2000
- Eficiența și siguranța Vasilip la pacienții cu hipercolesterolemie
- Efectele terapiei cu Leridip în hipertensiunea arterială esențială
- A multicenter, two-period, observational cohort study to evaluate the patient stabilization and cardiovascular resource utilization prior to, and after, the addition of Tirofiban to standard therapy for acute coronary ischemic syndromes (Unstable angina / Non-Q-wave myocardial infarction) - Protocol 903-0B
- An open-label, long-term, safety study of Ranolazine SR for chronic stable angina pectoris at doses of 750 mg and 1000 mg twice a day administered in combination with background anti-anginal therapy - Protocol #CVT 3034
- Prophylaxis of venous thromboembolism in patients with acute medical conditions requiring prolonged immobilization: a comparison of Dalteparin (Fragmin®) 5000 UI vs. Placebo in a double-blind, randomized, multicenter study - Protocol 524E-CVD-0042-033
- Effect of once-a-day oral administration of bedtime of S 5492 (a delayed release formulation of Perindopril) on safety and blood pressure in hypertension adult patients: a non-comparative optional titration (4.4 or 8.8 milligrams) 6-months open study - Protocol CL3-05492-005-INT
- A study of the new ACAT inhibitor CS-505 on the pregression of atherosclerosis as measured by 2-D and 3-D carotid ultrasound (ACAT inhibition plaque regression study) Protocol SE-505/14 (ACAT – APRES)
- Sibutramine cardiovascular morbidity / mortality outcomes study in overweight or obese subjects at risk of a cardiovascular event - Protocol M01-392
- A randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy, safety and tolerability of Ezetimibe 10 mg or placebo co-administered with existing Simvastatin 10 mg or 20 mg in attaining Low-Density Lipoprotein Cholesterol target levels in patients with hypercholesterolemia and coronary heart disease - Protocol 801-01
- A multicenter, double-blind, randomized, placebo-controlled, parallel group design study to evaluate the efficacy and safety of intravenous Tedisamil Sesquifumarate in the rapid conversion to normal sinus rhythm in female subjects with recent onset atrial fibrillation - Protocol S219.3.116
- An international randomized study evaluating the efficacy and safety of fondaparinux sodium versus controlled therapy and glucose-insulin-potassium infusion versus control in a broad range of patients with ST segment elevation acute myocardial infarction - 63131 MICHELANGELO: OASIS-6 (STEMI)

- A randomized, double blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan / amlodipine 160/10 mg versus amlodipine 10mg alone for 8 weeks in hypertensive patients who are adequately controlled on amlodipine 10 mg monotherapy - Protocol CVAA489A2306
- A multicenter, randomized, placebo-controlled, double-blind trial evaluating the effect of two doses of a vasopresin V2 receptor antagonist (SR121463B) on serum sodium in patients with dilutional hyponatremia - Protocol CPR-EFC5816-EN-E01
- Evaluation of anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4-month randomized double-blind parallel - group international multicenter study - Protocol CL3-16257-057
- BEAUTIFUL: Morbidity-mortality evaluation of the If inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction - Protocol CL3-16257-056
- A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250mg, 375mg and 500mg) administered twice daily for 16 weeks, on top of aspirin (325mg, qd) in men and women with non valvular atrial fibrillation at a low or intermediate risk for stroke - Protocol ITI101724
- A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Patients with Restricted Mobility, Protocol No. EFC 10572
- Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study Protocol No. 1235-SR-202-AF
- A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous iron carboxymaltose (Ferinject®) vs. placebo in patients with chronic heart failure, impaired renal function, iron deficiency and Hb level < 13.5 g/dl. Protocol No.FER-CARS-02
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficiency. Protocol No. 160HF301
- Studiu de faza III, Randomizat, dublu-orb, multicentric, multinational, grup paralel, evaluand eficacitatea si siguranta combinatiei Olmesartan Medoxomil/ Hydrochrolothiazide 40/12.5 mg fata de Olmesartan Medoxomil 40 mg monoterapie la pacientii cu hipertensiune esentiala. Protocol No. CS866CM-B-E303
- A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with 40 mg pravastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg pravastatin alone. Protocol No. CLF 0242780-01 05 04
- A randomized, double-blind, active-controlled, multicenter study of patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with atorvastatin 20 mg: A comparison of switching to a combination tablet ezetimibe/simvastatin (10mg/40mg) versus doubling the baseline dose to atorvastatin 40 mg. Protocol No. MK-06533A
- A phase 3, active (warfarin) controlled, randomized, double-blind, parallel-arm study to evaluate efficacy and safety of apixaban in preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Protocol No. CV185030
- A comparison of prasugrel and clopidogrel in acute coronary syndrome (ACS) subjects with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) who are medically managed – The TRILOGY ACS study. Protocol No. H7T-MC-TABY
- A randomized, double-blind, placebo controlled multi-center and parallel group study of the safety, tolerability and efficacy of YM150 in combination with standard treatment in secondary prevention of ischemic vascular events in subjects with acute coronary syndromes. The RUBY-1 study. Protocol No. 150-CL-201
- A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mortality when initiated early after hospitalization for acute decompensated heart failure. Protocol No. CSPP100A2368
- Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomized double-blind placebo-controlled international multicenter study (SIGNIFY). Protocol No. CL3-16257-083

ANEXE

▪ Lista de lucrări/publicații

1. Electrofiziologia intervențională - De la mecanism la terapie. Editura Mondocart Pres, 1999, ISBN 973-98894-1-7
2. Ghid de terapie a Fibrilației Atriale. G.A.Dan, L.Gherasim, D.D. Ionescu. In Ghiduri medicale, vol. 2, editura Infomedica, București 2002. ISBN: 973-9394-32-9/973-9394-69-8
3. Tahicardii ventriculare idiopatice maligne - de la mecanismul genetic și molecular la cel celular. In "Progrese in Cardiologie 2002" (ed. L.Gherasim), Editura Infomedica, 2002, ISBN: 973-9394-89-2
4. Sincopa, intoleranța ortostatică și disfuncția autonomă - spectrul unui diagnostic frustrant. G.A.Dan, Blair Grubb. In "Progrese in Cardiologie 2002" (ed. L.Gherasim), Editura Infomedica, 2002, ISBN: 973-9394-89-2
5. Studii clinice actuale. L. Gherasim, A. Ilieșiu, G.A. Dan, S. Bălănescu. In "Progrese in Cardiologie 2002" (ed. L.Gherasim), Editura Infomedica, 2002, ISBN: 973-9394-89-2
6. Anxietatea și simptomatologia cardiovasculară. G.A. Dan, R. Mihăilescu, M. Vintilă. Editura Rotech/Pro, 2004, ISBN: 973-8285-37-2
7. Manifestări cardiovasculare ale sindromului antifosfolipidic. In "Sindromul antifosfolipidic" (ed. C. Tănăsescu), editura Academiei Române, 2005, ISBN: 973-27-1240-6
8. Manual de curs pentru programul educațional - Protecția vasculară în ateroscleroza sistemică (PROVAS) - manual electronic - 2005, ediția a II-a - ISBN: 973-0-04277-2
9. Cardiologie - curs național pentru medici generaliști (manual electronic) – 2004
10. Fibrilația atrială: Certitudini și controverse. G-A. Dan, Dan Dobreanu, Dan Dominic Ionescu. In "Progrese in cardiologie" vol. I, (ed. Radu Capalaneanu), Editura Benett, 2006, ISBN: 973-87129-3-9
11. Moartea subita cardiaca: Mecanisme, stratificare de risc și prevenție. G-A. Dan, Dan Dobreanu, Dan Dominic Ionescu. In "Progrese in cardiologie" vol. II. Editura MediaMed Publicis, 2007, ISSN: 1843-3731
12. Prevention of arrhythmia recurrences by nonconventional antiarrhythmics after the first episode of paroxysmal atrial fibrillation. G.A. Dan, A. Dan, A. Buzea, I. Daha, C. Adam. Europace 2007; 9(suppl 3):38
13. Sincopa. G-A. Dan, Dan Dobreanu, C. Podoleanu. In "Progrese in cardiologie" vol. III. Editura MediaMed Publicis, 2008, ISSN: 1843-3731
14. Sindromul Brugada. In "Progrese in cardiologie". Editura T3 Info, 2009, ISSN 1843-3731
15. The dynamic nature of ventricular tachycardia initiation. G.A. Dan. Drugs of Today 2010; 46(10): 777-783
16. Ezetimibe/Simvastatin 10/40mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Ling PKH, Civeira F, Dan GA, et al. Lipids in Health and Disease 2012; 11:18
17. Implications of geographical variation on clinical outcomes of cardiovascular trials. Mentz RJ, Kaski JC, Dan GA, Goldstein S, et al. Am Heart J 2012;0: 1-10
18. Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Hober K, Connolly SJ, Kher A, Christy F, Dan GA, et al. Int J Clin Pract 2013; 67/6:516-526
19. Atrial Fibrillation Therapy (ed. G.A. Dan, J. Camm, A. Bayes De Luna), Springer 2013
20. Syncope in elderly patients - Is there a place for endomyocardial biopsy? C.A. Buzea, A.R. Dan, G.A. Dan. RomJInternMed 2013; 51/2: 67-71
21. Syncope units in Romania: A necessity. A.R. Dan, C.A. Buzea, G.A. Dan. RomJInternMed 2013; 51/1: 3-8
22. Characteristics of patients with atrial fibrillation and history of stroke or transient ischemic attack – some results from the FACTS database. Popescu R, Dan GA, Buzea A. Rom J Neurol 2013; 12/2: 53-57
23. Diagnosis orientation and risk stratification in syncope. Buzea CA, Dan AR, Dan GA. Rom J Neurol 2013; 12/3:105-112
24. Secondary prevention in patients with atrial fibrillation and stroke or transient ischemic attack – an insight from the FACTS programme. Popescu R, Dan GA, Buzea A. Rom J Neurol 2013; 12/3:130-135
25. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EuroObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Lip GYH, Laroche C, Dan GA, et al. Europace 2014; 16(3):308-19
26. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence. Martinez-Rubio A, Dan GA, Kaski JC. Expert Rev Cardiovasc Ther 2014 {early online}: 1-15
27. Systemic sclerosis biomarkers discovered using mass-spectrometry-based proteomics: a systematic review. P. Balanescu, A. Ladaru, E. Balanescu, C. Baicus, G.A. Dan. Biomarkers, 2014: early online 1-11; ISSN: 1354-750X (print), 1366-5804 (electronic)
28. Real world anti-thrombotic treatment in atrial fibrillation: the EuroObservational Research Programme Atrial Fibrillation General Pilot survey. Lip GYH, Laroche C, Dan GA, et al. Am J Med 2014; online 28 January 2014 <http://dx.doi.org/10.1016/j.amjmed.2013.12.022>
29. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the EuroObservational Research Programme Pilot survey on Atrial Fibrillation. Lip GYH, Laroche C, Boriani G, Cimaglia P, Dan GA, et al. Europace 2014; doi:10.1093/europace/euu155

N.B. 1. Publicarea după anul 2000 a 55 articole în reviste indexate internațional

N.B. 3. Sustinerea a peste 400 de conferințe pe teme de cardiologie în țară și în străinătate

apr.2015